OASM - Oasmia Pharmaceutical AB (publ)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.800
+0.200 (+12.500%)
At close: 3:51PM EDT
Stock chart is not supported by your current browser
Previous Close1.600
Open1.740
Bid0.010 x 100
Ask1.900 x 500
Day's Range1.711 - 1.855
52 Week Range0.800 - 3.165
Volume15,882
Avg. Volume34,460
Market Cap118.268M
Beta0.70
PE Ratio (TTM)N/A
EPS (TTM)-0.312
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000

    Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with an interest rate of 8 per cent per year directed to and placed with a limited group of investors and paid in cash (the “Private Placement”). The convertible instrument issue is expected to provide the Company with SEK 26,000,000 before transaction related costs.

  • GlobeNewswire2 months ago

    Oasmia Pharmaceutical AB (publ)

    Interim report for the period May 2017– January 2018. Commercial focus and lower cost base. THIRD QUARTER November 1, 2017– January 31, 2018.

  • GlobeNewswire2 months ago

    Oasmia Pharmaceutical’s Docecal program achieves significant development milestone

    Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer.. Uppsala, Sweden, February 19, 2018– Oasmia Pharmaceutical AB, ...

  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017
    Capital Cube7 months ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017

    Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended July 31, 2017. We analyze the earnings along side the following peers of Oasmia Pharmaceutical AB – OncoMed Pharmaceuticals, Inc., Omeros Corporation and Ohr Pharmaceutical, Inc. (OMED-US, OMER-US and OHRP-US) that have also reported for this period. Highlights Summary numbers: Revenues ... Read more (Read more...)

  • Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017
    Capital Cube9 months ago

    Oasmia Pharmaceutical AB :OASM-US: Earnings Analysis: Q4, 2017 By the Numbers : July 12, 2017

    Categories: Yahoo FinanceGet free summary analysis Oasmia Pharmaceutical AB reports financial results for the quarter ended April 30, 2017. Highlights Summary numbers: Revenues of USD 0.00 million, Net Earnings of USD -4.71 million. Gross margins narrowed from -51,783.05% to -85,334.09% compared to the same period last year, operating (EBITDA) margins now -82,834.09% from -49,876.27%. Change in operating ... Read more (Read more...)